Fact CheckerSign in

NCT07280715Recruiting

Investigating Real-Time Immunotherapy Symptoms Study

Digital Remote Patient Monitoring and Triage During Cancer Immunotherapy

Source: ClinicalTrials.gov · Last updated 4 Aug 2026

Brief summary (registry, in English)

The goal of this study is to evaluate the feasibility of using information from wearable devices and self-reported symptoms to remotely monitor patients during immunotherapy. The main questions it aims to answer are: * Is the digital remote patient monitoring tool feasible and acceptable to patients? * Do the alerts and guidance improve symptom management, quality of life, and engagement with the care team during treatment? Participants will: * Complete a demographic questionnaire at the beginning of the study and quality-of-life and health questionnaires at the beginning, midpoint, and end of study. * As feasible: At the beginning and end of the study, complete an in-person physical function assessment measuring balance (Short Physical Performance Battery). If participant is randomly assigned to the intervention group, they will also: * Complete weekly symptom ratings via digital remote patient monitoring tool * Wear a Fitbit activity tracker as feasible for 90 days. * At the end of the study, complete a semi-structured interview to provide feedback on the study.

Status (registry)
Recruiting
Study type
Interventional
Enrollment
40 (estimated)
First submitted
1 Dec 2025
Start date
17 Jun 2026
Primary completion date
31 Dec 2026
Lead sponsor
University of Pittsburgh
Diseases
Melanoma
NCT number
NCT07280715

What you commit to

  • Study type: Interventional
  • Planned participants: 40
  • From 17 Jun 2026 to the primary completion date, 31 Dec 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Age

  • under 18 years old; and

Other

  • unable to read and write in English

Who the study is looking for

  • receiving immune checkpoint inhibitor therapy at UPMC Hillman Cancer Center for melanoma;
  • age 18 years or older;
  • ability to read and write in English;
  • owns and uses a smartphone capable of running study applications

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
UPMC Hillman Cancer Center
Coordinator of this site? Confirm its status
PittsburghUnited StatesRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.